bYlok® bispecific pairing technology

Introduction to bYlok

Bispecific antibodies (bsAb) are emerging as an important class of therapeutics. Bispecific antibodies have increased potential for precision targeting and higher potency. Multi antigen binding can help reduce the development of subsequent clinical resistance. Different strategies have been used in the past to create bsAbs. However, key challenges remain with the developability of bispecific antibodies:

• Highly engineered formats that least resemble native proteins could have a higher risk of unwanted immunogenicity
• Expression of two different heavy and light chains in a single cell can create misassembled unwanted species. These impurities can be difficult to remove due to their similarity to the correct format.